Bayesian Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bayesian Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$504K	Buy	+808	New	+$550K	0.32%	88
2025 Q1	–	Sell	-952	Closed	-$678K	–	906
2024 Q4	$678K	Buy	+952	New	+$799K	0.08%	309
2021 Q2	–	Sell	-764	Closed	-$361K	–	609
2021 Q1	$361K	Sell	764 -167	-18%	-$81.3K	0.08%	309
2020 Q4	$450K	Buy	+931	New	+$503K	0.12%	229
2020 Q1	–	Sell	-7,830	Closed	-$2.94M	–	938
2019 Q4	$2.94M	Buy	+7,830	New	+$2.63M	0.5%	34
2018 Q1	–	Sell	-4,200	Closed	-$1.58M	–	777
2017 Q4	$1.58M	Buy	+4,200	New	+$1.7M	0.32%	78

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bayesian Capital Management's REGN Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 808 shares worth $504K. The stake represents 0.32% of the portfolio and ranks #88 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in REGN as recently as Q4 2024.

Bayesian Capital Management first reported a position in REGN in Q4 2017 and has held it in 6 quarters since. The position peaked at $2.94M in Q4 2019. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Bayesian Capital Management held 808 shares of Regeneron Pharmaceuticals worth $504K as of Q2 2026.
Regeneron Pharmaceuticals was a new Bayesian Capital Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.32% of Bayesian Capital Management's portfolio in Q2 2026, its #88 holding.
Bayesian Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
Bayesian Capital Management's Regeneron Pharmaceuticals position peaked at $2.94M in Q4 2019.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.